Inventor
Heinz Hillen
Inventor
Hassloch, DE
Overview
Patents· 30 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations27%
C07KPeptides25%
A61KPreparations for medical, dental or toiletry purposes22%
G01NInvestigating or analysing materials by determining their chemical or physical properties14%
C07DHeterocyclic compounds4%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests4%
C12NMicroorganisms or enzymes2%
C07BGeneral methods of organic chemistry1%
C07CAcyclic or carbocyclic compounds1%
C12YEnzymes1%
PatentTitleYear
10,538,581Anti-Ab globulomer 4D10 antibodies202010,464,976Amyloid b(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof201910,323,084Monoclonal antibodies against amyloid beta protein and uses thereof201910,208,109Monoclonal antibodies against amyloid beta protein and uses thereof201910,047,121Amyloid-beta binding proteins20189,951,125Ab conformer selective anti-Ab globulomer monoclonal antibodies20189,822,171'Amyloid-beta binding proteins'20179,540,432'Anti-Aβ globulomer 7C6 antibodies'20179,394,360'Aβ conformer selective anti-Aβ globulomer monoclonal antibodies'20169,359,430'Abeta conformer selective anti-Abeta globulomer monoclonal antibodies'20169,176,150'Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof'20159,062,101'Amyloid-beta binding proteins'20158,987,419'Amyloid-beta binding proteins'20158,895,004'Method for the treatment of amyloidoses'20148,877,190'Aβ conformer selective anti-Aβ globulomer monoclonal antibodies'20148,691,224'Anti-Aβ globulomer 5F7 antibodies'20148,497,072'Amyloid-beta globulomer antibodies'20138,455,626'Aβ conformer selective anti-aβ globulomer monoclonal antibodies'20138,263,558'Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins'20127,902,328'Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof'20116,683,055'Low molecular weight inhibitors of complement proteases'20046,610,691'Carboxylic acid derivatives, their production and use'20036,469,056'Pharmaceutically active compounds, their preparation and use as ECE-inhibitors'20026,358,983'Heterocyclically substituted -hydroxycarboxylic acid derivatives, method for producing the same and their use as endothelin receptor antagonists'20026,066,502'Endothelin converting enzyme (ECE)'20005,759,541'Recombinant fibrinogenases, the preparation and use thereof'19985,344,915'Proteins and the preparation thereof'19945,180,811'Proteins having a TNF action comprising TNF-fibromectin fusion protein'19935,157,106'N-terminal deletions of lymphotoxin, their preparation and use'19924,736,020'Purification of hTNF'1988Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1988–2004Patents assigned to BASF AG (8)· patent assignee history
1988–1993Based in Ludwigshafen, DE· patent location history
1994–2020Based in Hassloch, DE· patent location history
2002Based in Hassbloch, DE· patent location history
2012–2019Patents assigned to HILLEN HEINZ (10)· patent assignee history
2012–2019Patents assigned to BARGHORN STEFAN (9)· patent assignee history
2014–2020Patents assigned to ABBVIE DEUTSCHLAND (16)· patent assignee history
2014–2020Patents assigned to ABBVIE INC (13)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ABBVIE DEUTSCHLAND | 16 | 2014–2020 |
| ABBVIE INC | 13 | 2014–2020 |
| HILLEN HEINZself | 10 | 2012–2019 |
| BARGHORN STEFAN | 9 | 2012–2019 |
| BASF AG | 8 | 1988–2004 |
Locations
| Location | Patents | Span |
|---|---|---|
| Hassloch, DE | 26 | 1994–2020 |
| Ludwigshafen, DE | 3 | 1988–1993 |
| Hassbloch, DE | 1 | 2002 |